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Available online 4 October 2016Primary aldosteronism (PA) is the most common form of secondary hypertension. Mutations in KCNJ5, ATP1A1,
ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism
(FH). A recurrent mutation in CACNA1H (coding for Cav3.2) was identiﬁed in a familial form of early onset PA.
Here we performed whole exome sequencing (WES) in patients with different types of PA to identify new sus-
ceptibility genes.
Four different heterozygous germline CACNA1H variants were identiﬁed. A de novo Cav3.2 p.Met1549Ile variant
was found in early onset PA and multiplex developmental disorder. Cav3.2 p.Ser196Leu and p.Pro2083Leu were
found in two patients with FH, and p.Val1951Glu was identiﬁed in one patient with APA. Electrophysiological
analysis of mutant Cav3.2 channels revealed signiﬁcant changes in the Ca2+ current properties for all mutants,
suggesting a gain of function phenotype. Transfections of mutant Cav3.2 in H295R-S2 cells led to increased aldo-
sterone production and/or expression of genes coding for steroidogenic enzymes after K+ stimulation. Identiﬁca-
tion of CACNA1H mutations associated with early onset PA, FH, and APA suggests that CACNA1H might be a
susceptibility gene predisposing to PAwith different phenotypic presentations, opening newperspectives for ge-
netic diagnosis and management of patients with PA.






Voltage dependent calcium channel
Hypertension1. Introduction
Primary aldosteronism (PA) is the most common form of secondary
arterial hypertension, with an estimated prevalence of ∼10% in referred
patients, 4% in primary care (Hannemann andWallaschofski, 2012), and
20% in patients with resistant hypertension (Calhoun et al., 2002;
Douma et al., 2008). It is characterised by hypertension, hypokalemia,terone producing adenoma; FH,
ing.
diovascular Research Center –
Fernandes-Rosa),
. This is an open access article underand inadequate high levels of plasma aldosterone for low levels of plas-
ma renin (Funder et al., 2016). Aldosterone-producing adenoma (APA)
or bilateral adrenal hyperplasia (BAH) are the most frequent causes of
PA (Amar et al., 2010).
Somatic mutations in KCNJ5 (encoding the potassium channel
GIRK4), ATP1A1 (encoding the α1 subunit of the Na+/K+-ATPase),
ATP2B3 (encoding the plasma membrane Ca2+-ATPase, type 3 PMCA3),
and CACNA1D (encoding theα1 subunit of the L-type voltage-dependent
calcium channel Cav1.3) were identiﬁed in≈50% of APA (Azizan et al.,
2013; Beuschlein et al., 2013; Choi et al., 2011; Fernandes-Rosa et al.,
2014; Scholl et al., 2013). KCNJ5 and ATP1A1mutations are responsible
for chronic zona glomerulosa cell membrane depolarization leading to
opening of voltage-dependent calcium channels, while ATP2B3 muta-
tions affect intracellular calcium recycling and CACNA1Dmutations leadthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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voltages (Azizan et al., 2013; Beuschlein et al., 2013; Choi et al., 2011;
Scholl et al., 2013). All these genetic abnormalities converge towards in-
creasing intracellular calcium concentration with activation of calcium
signaling triggering increased expression of CYP11B2 encoding aldoste-
rone synthase, which catalyzes the last steps of aldosterone biosynthesis.
While the majority of cases of PA are sporadic, 1–5% of cases are fa-
milial forms (Zennaro et al., 2015). Familial hyperaldosteronism (FH)
type I is a disease with autosomal dominant transmission due to un-
equal crossing-over of geneticmaterial between the genes coding for al-
dosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1). Thus
aldosterone biosynthesis is regulated by ACTH resulting in a circadian
pattern of aldosterone production which parallels that of cortisol pro-
duction and which is suppressible by dexamethasone (Sutherland et
al., 1966). FH type II (FH-II) is not remediable by glucocorticoids and is
diagnosed on the basis of two or more affected family members in the
absence of the chimeric CYP11B1/CYP11B2 gene. The genetic cause of
FH-II is still unknown, but a linkage to chromosomal region 7p22 has
been established in some families (Lafferty et al., 2000; So et al., 2005;
Sukor et al., 2008). Recurrent germline mutations in KCNJ5 (Adachi et
al., 2014; Charmandari et al., 2012; Choi et al., 2011; Monticone et al.,
2013; Mulatero et al., 2012; Scholl et al., 2012) were identiﬁed in FH
type III (FH-III) and are associatedwith phenotypes of different severity.
De novo germline CACNA1Dmutations were described in two children
with PASNA (Primary aldosteronism, seizures, and neurological abnor-
malities), a syndrome featuring PA and neuromuscular abnormalities
(Scholl et al., 2013). More recently, a recurrent germline mutation in
CACNA1H (encoding the pore-forming α1 subunit of the T-type volt-
age-dependent calcium channel Cav3.2) (p.Met1549Val) was identiﬁed
in 5 children with PA before age 10. Familial analysis revealed autoso-
mal dominant transmission of CACNA1H mutations with incomplete
penetrance and a new form of familial PA (Scholl et al., 2015).
Despite these recent advances, the pathogenesis of a large propor-
tion of sporadic and familial cases of PA has not been elucidated. The
aim of the present study was to identify new genetic abnormalities in
patients with PA. To this purpose we have performed whole exome se-
quencing (WES) in patients with different types of PA. We identiﬁed
four germline variations in CACNA1Hwhich affect the electrophysiolog-
ical and functional properties of the channel, leading to increased
CYP11B2 expression and aldosterone production.
2. Subjects and Methods
2.1. Patients
Patients with PA were recruited between 1994 and 2012 within the
COMETE (COrtico-et MEdullo-surrénale, les Tumeurs Endocrines)
network or in the context of genetic screening for familial
hyperaldosteronism at the genetics department of the HEGP. Methods
for screening and subtype identiﬁcation of PAwere performed according
to institutional and Endocrine Society guidelines (Funder et al., 2008;
Letavernier et al., 2008). In patients diagnosed with primary aldosteron-
ism, a thin slice CT scan or MRI of the adrenal and/or an adrenal venous
sampling (AVS) were performed to differentiate between unilateral and
bilateral aldosterone hypersecretion. All patients gave written informed
consent for genetic and clinical investigation. Procedures were in accor-
dance with institutional guidelines. The diagnosis of adrenocortical ade-
noma was histologically conﬁrmed after surgical resection. A ﬁnal
diagnosis of APA, diagnosed by CT scanning and AVS, was considered
“proven” when the following conditions were satisﬁed: 1) histological
demonstration of adenoma; 2) normalization of hypokalemia, if present;
3) cure or improvement of hypertension; 4) normalization of ARR and/or
suppressibility of aldosterone under saline load (Mulatero et al., 2009;
Rossi et al., 2006). All patients gavewritten informed consent for genetic
and clinical investigation within each individual institution. Procedures
were in accordance with institutional guidelines.2.2. DNA Isolation
Tumor DNA was extracted using QIAamp DNA midi kit (Qiagen,
Courtaboeuf Cedex, France). DNA from peripheral blood leukocytes
was prepared using salt-extraction.
2.3. Whole Exome Sequencing and Variant Detection
Exomes were enriched in solution and indexed with SureSelect XT
Human All Exon 50 Mb kits (Agilent). Sequencing was performed as
100 bp paired-end runs on HiSeq2000 systems (Illumina). Pools of 12
indexed libraries were sequenced on four lanes. Image analysis and
base calling was performed using Illumina Real Time Analysis. CASAVA
1.8 was used for demultiplexing. BWA (v 0.5.9) with standard parame-
ters was used for read alignment against the human genome assembly
hg19 (GRCh37). We performed single-nucleotide variant and small in-
sertion and deletion (indel) calling speciﬁcally for the regions targeted
by the exome enrichment kit, using SAMtools (v 0.1.18). Subsequently
the variant quality was determined using the SAMtools varFilter script.
We used default parameters, with the exception of the maximum read
depth (-D) and the minimum P-value for base quality bias (−2),
whichwe set to 9999 and 1e-400, respectively. Additionally, we applied
a custom script to mark all variants with adjacent bases of low median
base quality. All variants were then annotated using custom Perl scripts.
Annotation included information about known transcripts (UCSC
Known Genes and RefSeq genes), known variants (dbSNP v 135), type
of mutation, and - if applicable – amino acid change in the correspond-
ing protein. The annotated variants were then inserted into our in-
house database.
To discover putative somatic variants, we queried our database to
show only those variants of a tumor that were not found in the corre-
sponding control tissue. To reduce false positives we ﬁltered out vari-
ants that were already present in our database, had variant quality
b40, or failed one of the ﬁlters from the ﬁlter scripts. We thenmanually
investigated the raw read data of the remaining variants using the Inte-
grative Genomics Viewer (IGV).
2.4. Sanger Sequencing
CACNA1H DNA was ampliﬁed using intron-spanning primers de-
scribed in Supplemental Table S1. PCR was performed on 100 ng of
DNA in a ﬁnal volume of 25 μL containing 0.75 mM MgCl2, 400 nM of
each primer, 200 μM deoxynucleotide triphosphate, and 1.25 U Taq
DNA Polymerase (Sigma). Cycling conditions for CACNA1Hwere as pre-
viously described (Hubert et al., 2011) with an annealing temperature
of 60 °C. Direct sequencing of PCR products was performed using the
ABI Prism Big Dye Terminator® v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA) on an ABI Prism 3700 DNA Analyzer (Ap-
plied Biosystems).
2.5. Site Directed Mutagenesis
The Cav3.2196Leu, Cav3.21549Ile, Cav3.21951Glu and Cav3.22083Leu con-
structs, coding for the mutant forms of Cav3.2 were generated by site-
directed mutagenesis using the QuikChange II XL site-directed muta-
genesis kit (Agilent). The mutations were introduced into the human
Cav3.2 HA cDNA fragment inserted into pcDNA3.1 (Dubel et al., 2004)
and their presence conﬁrmed by Sanger sequencing.
2.6. Cell Culture and Transfection Protocols
tsA-201 cells were cultivated in DMEM supplemented with
GlutaMax, 10% fetal bovine serum and 1% penicillin/streptomycin
(Invitrogen). Transfections were performed using jet-PEI (QBiogen)
with a DNAmix (1.5 μg total) containing 0.5% of a GFP encoding plasmid
and 99.5% of either of the plasmid constructs coding either for the wild-
227G. Daniil et al. / EBioMedicine 13 (2016) 225–236type or the mutant human Cav3.2 T-type channels. Two days after
transfection, tsA-201 cells were dissociated with Versene (Invitrogen)
and plated at a density of ~35 × 103 cells per 35 mm Petri dish for elec-
trophysiological recordings, which were performed the following day.
The human adrenocortical carcinoma cell line H295R strain 2
(H295R-S2) was kindly provided by W. E. Rainey (Wang et al., 2012).
H295R-S2 cells were cultured in DMEM/Eagle's F12 medium (GIBCO,
Life technologies, Carlsbad, CA) supplemented with 2% Ultroser G
(PALL life sciences, France), 1% insulin/transferrin/selenium Premix
(GIBCO, Life technologies, Carlsbad, CA), 10 mM HEPES (GIBCO, Life
technologies, Carlsbad, CA), 1% penicillin, and streptomycin (GIBCO,
Life technologies, Carlsbad, CA) andmaintained in a 37 °C humidiﬁed at-
mosphere (5% CO2).
2.7. Electrophysiological Recordings
Macroscopic currents were recorded at room temperature using an
Axopatch 200B ampliﬁer (Molecular Devices). Borosilicate glass pi-
pettes had a resistance of 1.5–2.5 M Ohm when ﬁlled with an internal
solution containing (in mM): 140 CsCl, 10 EGTA, 10 HEPES, 3 Mg-ATP,
0.6 GTPNa, and 3 CaCl2 (pH adjusted to 7.25 with KOH, ~315 mOsm, ~
100 nM free Ca2+ using the MaxChelator software, http://
maxchelator.stanford.edu/). The extracellular solution contained (in
mM): 135 NaCl, 20 TEACl, 2 CaCl2, 1 MgCl2, and 10 HEPES (pH adjusted
to 7.25 with KOH, ~330 mOsm). Recordings were ﬁltered at 5 kHz. Cur-
rent–voltage curves (I–V curves) were ﬁtted using a combined
Boltzmann and linear Ohmic relationships, where I = Gmax × (Vm−
Vrev) / (1 + exp((Vm− V0.5) / slope factor)). Similarly, steady-state
inactivation curves were ﬁtted using the Boltzmann equation where I/
I max = 1/(1 + exp((Vm− V0.5) / slope factor)). Data were analyzed
using pCLAMP9 (Molecular Devices, Sunnyvale, CA) and GraphPad
Prism (GraphPad software Inc., San Diego, CA) software. Results were
presented as the mean ± SEM, and n was the number of cells.
2.8. Functional Studies in H295R-S2
For functional experiments, H295R-S2 cells were seeded to tissue
culture dishes 100 in groups of 4,000,000 cells per dish, andmaintained
at the conditions described. After 24 h, cells were transfected with WT
or mutant forms of CACNA1H (Cav3.2196Leu, Cav3.21549Ile, Cav3.21951Glu,
and Cav3.22083Leu) using Effectene (Qiagen, Valencia, CA). 24 h post
transfection, cells were transferred in 24 well-plates and serum de-
prived in DMEM/F12 containing 0.1% Ultroser G for 24 h and then incu-
bated for another 24 h with fresh medium containing 0.1% Ultroser G
with no secretagogue (basal) or 10 nM of AngII (A-II 10 nM), or
12mMK+ (K+ 12mM). At the end of this incubation time, supernatant
and cells from each well were harvested for aldosterone measurement
and RNA extraction. For eachmutant, three experiments were indepen-
dently conducted in triplicates or quadriplicates.
2.9. RNA Extraction and RT-qPCR
Total RNAwas extracted in Trizol reagent (Ambion Life technologies,
Carlsbad CA) according to the manufacturer's recommendations. After
deoxyribonuclease I treatment (Life Technologies, Carlsbad, CA),
500 ng of total RNA was retrotranscribed (iScript reverse transcriptase,
Biorad, Hercules, CA). Primers used for qPCR are described in Table S2.
The quantitative PCR was performed using SYBRgreen (Sso advanced
universal SyBr Green supermix, Biorad, Hercules, CA) on a C1000
touch thermal cycler of Biorad (CFX96 Real Time System), according
to the manufacturer's instructions. Controls without template were in-
cluded to verify that ﬂuorescence was not overestimated from primer
dimer formation or PCR contaminations. RT-qPCR products were ana-
lyzed in a post ampliﬁcation fusion curve to ensure that a single
amplicon was obtained. Normalization for RNA quantity, and reverse
transcriptase efﬁciency was performed against three reference genes(geometric mean of the expression of Ribosomal 18S RNA, HPRT, and
GAPDH), in accordance with the MIQE guidelines (Bustin et al., 2009).
CACNA1H expression was quantiﬁed to normalize for transfection efﬁ-
ciency. Quantiﬁcationwas performed using the standard curvemethod.
Standard curveswere generated using serial dilutions from a cDNApool
of all samples of each experiment, yielding a correlation coefﬁcient of at
least 0.98 in all experiments.
2.10. Aldosterone and Protein Assays
Aldosterone levels were measured in cell culture supernatants by
ELISA. Aldosterone antibody and aldosterone-3-CMO-biotin were kind-
ly provided by Dr Gomez-Sanchez (Gomez-Sanchez et al., 1987). Aldo-
sterone concentrations were normalized to cell protein concentration
(determined using Bradford protein assay) and CACNA1H expression.
2.11. Statistical Analyses
Quantitative variables are reported as means ± standard deviation
when Gaussian distribution or medians and interquartile range when
no Gaussian distribution, and compared with unpaired t-test or Mann-
Whitney test respectively. Multiple comparisons were analyzed by
one-way ANOVA followed by Bonferroni test. Statistical analysis of elec-
trophysiological measures were performedwith one-way ANOVA com-
bined with a Tukey post-test (*P b 0.05, **P b 0.01, ***P b 0.001).
Categorical variables are reported as percentages and compared with
Fisher's exact test. A P value b 0.05 was considered signiﬁcant for com-
parisons between 2 groups. For functional experiments, all results were
expressed as mean ± SEM of at least three separate experiments per-
formed in triplicate or quadruplicate. Analyses were performed using
Prism5 (GraphPad software Inc., San Diego, CA).
3. Results
3.1. Whole Exome Sequencing in Patients With PA
In order to identify new genes in PA, WES was performed on
germline DNA from a young patient with early onset hypertension
and hyperaldosteronism and his parents under the hypothesis of a de
novo mutation. Whole exome sequencing was also performed in 10
subjects from the FrenchWest Indies with a family history of hyperten-
sion and PA under the hypothesis of a founder effect. For all these pa-
tients the presence of the chimeric CYP11B1/CYP11B2 gene and of
recurrent KCNJ5 mutations had been excluded. We sought previously
unreported (dbSNP, Helmholtz exome database) and protein altering
variants in genes that occurred in more than one subject. Among
germline variants observedwith this approach,we identiﬁed threemis-
sense variants in the CACNA1H gene, coding for the pore-forming sub-
unit of Cav3.2, affecting conserved residues of the protein (Fig. 1A–C).
All variants were conﬁrmed by Sanger sequencing of independent
DNA samples (Fig. 1A–C).
The germline CACNA1H variant c.4647GNC (p.Met1549Ile) was iden-
tiﬁed in subject K055-3 but not in his asymptomatic parents (K055-1
and K055-2), suggesting a de novo mutation responsible for his pheno-
type (Fig. 1A). This variant was absent among N120,000 alleles se-
quenced from diverse populations in the Exome Aggregation
Consortium (ExAC) and the Helmholtz exome databases. The variation
CACNA1H p.Met1549Ile is located in the transmembrane segment S6
of the repeat domain III of Cav3.2 (Fig. 1A and E) and modiﬁes the
same amino acid as the CACNA1H p.Met1549Val variant recently report-
ed in FH-IV (Scholl et al., 2015).
The germline CACNA1H variation c.587CNT (p.Ser196Leu) was iden-
tiﬁed in subject K475-1 with a family history of PA (Table 1). The same
variant was identiﬁed by Sanger sequencing in one sister (K475-2)who
also presented resistant hypertension and PA (Fig. 1B). The variant af-
fects an amino acid located in the voltage sensor region on the
Fig. 1. CACNA1H variations identiﬁed in patients with PA. A–D. Pedigrees, Sanger sequencing chromatograms, alignment, and conservation of residues encoded by CACNA1H orthologs. A.
c.4647GNC (p.Met1549Ile); B. c.587CNT (p.Ser196Leu); C. c.6248CNT (p.Pro2083Leu); D. c.5852TNA (p.Val1951Glu). Subjects with PA are shownwith black symbols, subjects with arterial
hypertension with grey symbols and non-affected subjects are shown with white symbols. E. Transmembrane structure of Cav3.2 representing the four homologous domains I–IV each
with six transmembrane spans (Segments (S) 1–6), and cytoplasmic N- and C-termini. The pore of T-type channels is formed by the tetrameric arrangement of the four domains and
is lined by the S6 segment in the intracellular part, while the S4 segment serves as the voltage sensor. The Met1549Ile mutation is located in S6 of repeat III and p.Ser196Leu in S4 of
repeat I; p.Pro2083Leu and p.Val1951Glu are located in the C-terminal cytoplasmic domain.
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This variant was absent from the ExAC andHelmholtz exomedatabases.
A third CACNA1H variant c.6248CNT, changing Proline 2083 into Leu-
cine, was identiﬁed in a second subject with a family history of PA
(K173-1, Fig. 1C); this variant is extremely rare, as it was found in 3
out of 92090 alleles in ExAC. Pro2083Leu is located in the C-terminal cy-
toplasmic domain of Cav3.2 (Fig. 1E) and was also identiﬁed in one
brother (K173-2) diagnosed with PA (Fig. 1C).
To investigate whether CACNA1H could also be involved in PA asso-
ciated with APA, we retrieved WES data from 23 patients with APATable 1
CACNA1H variations identiﬁed in patients with PA.
Patient Form of PA Variant cDNA Variant protein Domain
K055-3 Young onset c.4647GNC p.Met1549Ile Tm S6, repeat III
K475-1 FH-II c.587CNT p.Ser196Leu Tm S4, repeat I
K173-1 FH-II c.6248CNT p.Pro2083Leu Cytoplasmic
K135-1 Sporadic APA c.5852TNA p.Val1951Glu Cytoplasmic
TM: transmembrane; FH-II: familial hyperaldosteronism type II; NM_02198; NP_066921.without known recurrent somaticmutations. A germline CACNA1Hmis-
sense variant (c.5852TNA/p.Val1951Glu) was found in one patient with
APA (subject K135-1). This variationwas conﬁrmed by Sanger sequenc-
ing both in germline and somatic APA DNA (Fig. 1D); its frequency is 3/
18506 alleles in ExAC,whereas it is absent from theHelmholtz database.
It is located in the C-terminal cytoplasmic domain of Cav3.2, in a region
possibly implicated in fast channel activation. Similar to the other vari-
ants it affects a highly conserved residue of Cav3.2 (Fig. 1D and E).
3.2. Clinical Features of Patients With CACNA1H Variants
Clinical and biochemical characteristics of subjects carrying
CACNA1H variants are described in Table 2.
Subject K055-3 is a 22 year old male of European ancestry. At age 2
months, he underwent a pyloromyotomy to treat a pyloric stenosis. In
the days following the discharge, the child was readmitted because of
ENT infection and amajor hypokalemia (1,7mmol/L) associated tomet-
abolic acidosis was discovered. Evaluation revealed high plasma aldo-
sterone (3324 pmol/L; NV for age: 140-2500 pmol/L) despite
suppressed renin (b1 mUI/L), and arterial hypertension. The diagnosis
Table 2
Patients characteristics.
K055-3 K475-1 K475-2 K173-1 K173-2 K135-1
Sex M M F M M F
Form of PA Early-onset FH-II FH-II FH-II FH-II Sporadic, APA
Age at HTN dg 2 m 36 y 32 y 34 y 37 y 48 y
Age at PA dg 2 m 51 y 37 y 44 y 39 y 50 y
SBP at PA dg (mmHg) 110 155 153 154 160 142
DBP at PA dg (mmHg) 70 95 97 104 98 87
BMI at PA dg (kg/m2) – 27.8 32.4 25.8 34.7 23.4
Lowest plasma K+ (mmol/l) 1.7 2.7 2.9 3.9 2.9 2.5
Urinary aldosteronea (nmol/24 h) – 104 – – – 118
Plasma aldosterone (pmol/l)b 3324 965 804 753 688 620
Plasma renin (mU/l) b1 3.7 2.6 3 b1 1.5
ARR (pmol/mU)c 624 193 160.8 150.6 137.6 124
Adrenal abnormalities on CT No Bilateral nodules no No Left adrenal hyperplasia Left adrenal nodule
AVS lateralisation index – 48 (left) – – – –
Adenoma size (mm) – 11 – – – 8
PA: primary aldosteronism; dg: diagnosis; m,months; y, years; HTN: hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: bodymass index; K: potassium; ARR:
aldosterone to renin ratio; AVS: adrenal venous sampling. Hormonal data are at diagnosis of PA. a: PA diagnostic criteria is ≥63 nmol/24 h. b: PA diagnostic criteria is ≥500 pmol/L. For
children at 2 months of age the upper normal limit of plasma aldosterone is 2500 pmol/L. c: PA diagnostic criteria is ≥64 pmol/mU.
Table 3
Expression of calcium channels in control adrenal cortex (CA) and aldosterone producing
adenoma (APA)a.
Gène Protein Type CA APA P value
CACNA1C Cav1.2 L-type 7.182 21.45 P b 0.0001
CACNA1D Cav1.3 L-type 2.252 3.684 P = 0.0607
CACNA1I Cav3.3 T-type 1.864 1.644 P = 0.1148
CACNA1H Cav3.2 T-type 1.682 1.651 P = 0.6029
CACNA1E Cav2.3 R-type 1.441 3.302 P = 0.0009
CACNA1A Cav2.1 P/Q-type 1.272 3.399 P b 0.0001
CACNA1G Cav3.1 T-type 0.6967 0.6747 P = 0.6130
CACNA1S Cav1.1 L-type 0.5508 0.7413 P = 0.9235
CACNA1B Cav2.2 N-type 0.5397 0.5753 P = 0.5948
CACNA1F Cav1.4 L-type 0.4809 0.5642 P = 0.3467
a mRNA expression was retrieved from a transcriptome studies including 123 APA and
11 CA (Boulkroun et al., 2012). P-values indicate the differences between CA and APA.
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improvement of hypertension and hypokalemia. On CT scan, adrenals
were normal and no nodules were identiﬁed. Spironolactone could be
discontinued between 12 and 16 years of age without recurrence of
major hypokalemia, but renin remained suppressed. Because of the re-
appearance of high blood pressure, spironolactone was reintroduced
at age 19 years and 10months. His blood pressure is currently well con-
trolled. At 7 years of age the patient showed mild mental retardation,
social skills alterations and learning disabilities. He was diagnosed
3 years later with multiplex developmental disorder. Brain MRI was
normal and he didn't show any muscle weakness. Genetic screening
for FH-I and FH-IIIwasnegative. His parents and siblings have nohistory
of hypertension or hyperaldosteronism (Fig. 1A).
Patient K475-1 is a 64 years old male from the French West Indies.
Hewas diagnosedwith arterial hypertension at 36 years of age in a con-
text of familial hypertension. His mother and three sisters were hyper-
tensive. At age 51 years he was seen at the hypertension unit of the
HEGP because of hypokalemia (2,7 mmol/L) associated with resistant
hypertension. Biochemical analysis showed high levels of plasma and
urinary aldosterone (965 pmol/L and 104 nmol/24 h, respectively)
and low plasma renin (3,7 mU/L), conﬁrming the diagnosis of PA. At
CT scan, two nodules were identiﬁed on the right (21 mm) and left
(11 mm) adrenals. AVS was performed showing a lateralization index
of 48 on the left. The patient underwent left adrenalectomy with im-
provement of hypertension two months after surgery. The patient was
lost at followup and hormonal curewas not assessed. His younger sister
(subject K475-2) showed resistant hypertension diagnosed at the age of
32 years, requiring 4 antihypertensive drugs to control blood pressure,
associated with episodes of hypokalemia. At evaluation, she presented
with high plasma aldosterone (804 pmol/L) and low plasma renin (2,6
mU/L). CT revealed no adrenal abnormality, but AVSwas not performed
and the patient was lost at follow up.
Patient K173-1 is a 64 years oldmale fromWest Indies. Hewas diag-
nosedwith resistant hypertension at the age of 34 years, requiring three
antihypertensive drugs to control blood pressure. His parents, two sis-
ters, and one brother were also hypertensive (Fig. 1C). Diagnosis of PA
was made at age 44 years in the presence of high plasma aldosterone
(753 pmol/L) and low plasma renin (3 mU/L), without hypokalemia.
There was no adrenal abnormality on CT scan. He did not continue the
follow up in our department. His younger brother (K173-2) had a histo-
ry of hypertension since age 39 years associated with hypokalemia (2,8
mmol/L) and obesity. Endocrine evaluation showed high plasma aldo-
sterone (688 pg/mL) and suppressed plasma renin (b1 mU/L) levels.
CT scan revealed left adrenal thickening without individualized adeno-
ma. The patient was lost at follow up.Patient K135-1 is a 60 years old female of European ancestry. She
was diagnosed with hypertension at age 48 years with no history of fa-
milial hyperaldosteronism or hypertension. PA was diagnosed at age
50 years based on hypokalemia (2,5 mmol/L), high plasma aldosterone
(620 pmol/L), high urinary aldosterone (118 nmol/24 h), and low plas-
ma renin (1,5 mU/L). An 8 mm left adrenal nodule was identiﬁed on CT
scan. AVS was not performed. The patient underwent left adrenalecto-
my with normalization of blood pressure and hormonal cure at 8
months of follow up (plasma aldosterone 269 pmol/L, plasma renin
12,9mU/L, and blood pressure 121/76mmHgwithout antihypertensive
drugs). The resected adrenal showed an 8mm large adenomawith pre-
dominance of zona fasciculata like cells. No somatic mutations were
identiﬁed in KCNJ5, CACNA1D, ATP1A1, ATP2B3, or CTNNB1.
3.3. CACNA1H mRNA Expression in Normal Adrenal Cortex and APA
To investigate CACNA1H expression in the normal adrenal gland and
APA, we retrieved mRNA expression data of L-type and T-type voltage-
dependent calcium channels from a transcriptome study performed on
123 APA and 11 control adrenal cortices (Boulkroun et al., 2012).
CACNA1H was highly expressed in both normal adrenal cortex and
APA, being one of the most expressed T-type voltage-gated calcium
channels (Table 3). No difference in CACNA1H mRNA expression was
observed between normal adrenal cortex and APA.
3.4. Electrophysiological Analysis of Mutant Cav3.2 Channels
To assess the functional consequences of Cav3.2 variants on electro-
physiological properties of the channels, we expressedwild type Cav3.2
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Cav3.21951Glu and Cav3.22083Leu) in tsA-201 cells and performed
whole-cell patch clamp recordings. Fig. 2A shows typical T-type Ca2+
current recordings using depolarizing potentials (from−80 mV to +
30mV) from a holding potential (HP) at -100mV, obtained on a cell ex-
pressing the Cav3.21549Ile mutant (bottom traces), and compared to a
family of control T-type currents (Cav3.2WT, upper traces). The corre-
sponding current-voltage (I\\V) relationship obtained for the
Cav3.21549Ile mutant revealed a signiﬁcant leftward shift in the volt-
age-dependent activation (Fig. 2B, blue trace) with a potential for half-
activation (V1/2) of−53.47± 0.77mV, compared to the V1/2 for activa-
tion of−43.81± 1.15mV for theWT channels (see Table 4). No signif-
icant difference in the V1/2 for activation was found for the three other
mutants Cav3.2196Leu, Cav3.21951Glu and Cav3.22083Leu. Importantly,
Ca2+ current kinetics of Cav3.2 channels were also markedly affected
by the Cav3.21549Ile mutation (Fig. 2A). Measurement of the time-con-
stant for activation (Tau act, Fig. 2C) and inactivation (Tau inact, Fig.
2D) revealed signiﬁcant slowing in activation and inactivation kinetics
for Cav3.21549Ile and Cav3.2196Leu, while no change was observed for
Cav3.21951Glu and Cav3.22083Leu (Table 4). Steady-state inactivation
properties of Cav3.2 mutants were also affected (Fig. 3A), as evidenced
by the signiﬁcant leftward shift of the potential for half-inactivation (V1/
2, inact) for Cav3.21549Ile (Table 4). In addition, a change in the inactiva-
tion slope constant (k) was identiﬁed for anothermutant, Cav3.22083Leu,
which exhibited signiﬁcantly higher values for the inactivation slope
factor, k (Table 4). Steady-state activation and inactivation properties
of T-type calcium channels are crucial to determine the T-type “window
current”, a physiologically relevant Ca2+ entry that occurs in the range
of the resting membrane potential (Rossier, 2016). Estimates of the
window current for the four Cav3.2 mutants are presented in Fig. 3B,
compared to the window current of WT Cav3.2 channels (black trace).
A larger and more negatively shifted window current was observed
for the Cav3.21549Ile mutant, while the window current for the
Cav3.22083Leu mutant was reduced and shifted towards more positiveFig. 2. Electrophysiological analyses of WT and mutant Cav3.2 channels. A. Representative fa
ranging from−80 to +30 mV from a HP of−100 mV. The dotted line indicates the zero cur
in panel A for Cav3.2WT andmutant Cav3.2 channels. C–D. Activation kinetics (C) and inactivamembrane potential. In addition, while recovery from inactivation
was signiﬁcantly delayed for Cav3.21549Ile (Fig. 3C, Table 4), it was signif-
icantly faster for the three other mutants, indicating that Cav3.2196Leu,
Cav3.21951Glu and Cav3.22083Leu mutations could favor larger Ca2+
entry during repetitive electrical activities (Table 4). In addition, deacti-
vation kineticswas strongly slowed for Cav3.21549Ile (Fig. 4D), compared
to WT Cav3.2 channels and the three other Cav3.2 mutants. Analysis of
the electrophysiological properties that could be affected by the Cav3.2
variants also identiﬁed a marked change in voltage-dependent facilita-
tion (Fig. 4) for Cav3.2196Leu, Cav3.21951Glu and Cav3.22083Leu (Fig. 4B),
that is not observed for WT Cav3.2 channels (Fig. 4A). This paired-
pulse protocol, using a depolarizing prepulse to +100 mV, revealed a
marked increase in the current amplitude for these three mutants but
not for Cav3.21549Ile (Fig. 4C, Table 4), indicating that their activity
could be enhanced during repetitive action potentials. Altogether,
these electrophysiological data support a gain of channel activity for
all four Cav3.2 mutants.
3.5. Effect of Cav3.2 Mutations on Aldosterone Biosynthesis
Aldosterone production was determined in adrenocortical H295R-
S2 cells transiently transfected with Cav3.2WT or the mutant forms of
Cav3.2 in basal condition and 24-hours after stimulationwith angioten-
sin 2 (AngII) (10 nM) or K+ (12 mM). In basal condition, a non-statisti-
cal signiﬁcant increase of aldosterone production was observed in cells
expressing themutant forms of Cav3.2 compared to Cav3.2WT (Fig. 5A to
D). Stimulation of cells with AngII or K+ led to increased aldosterone
production, compared to basal condition, in cells expressingWT or mu-
tated channels (Fig. 5A to D). After K+ stimulation cells overexpressing
Cav3.21549Ile and Cav3.2196Leu displayed a 4.5-fold (Cav3.21549Ile,
p b 0.0001) and 2.5-fold (Cav3.2196Leu, p b 0.001) higher increase of al-
dosterone biosynthesis compared to cells overexpressing Cav3.2WT
(Fig. 5A and B); the levels of aldosterone were also increased by 40%
in cells overexpressing the mutants Cav3.22083Leu and Cav3.21951Glu,milies of Cav3.2 WT and Cav3.21549Ile currents elicited by a series of depolarization steps
rent level. B. Current-voltage (I–V) relationship obtained from experiments as illustrated
tion kinetics (D) as a function of the potential for Cav3.2WT and mutant Cav3.2 channels.
Table 4
Electrophysiological properties of WT and mutant Cav3.2 channels.
Cav3.2WT Cav3.2196Leu Cav3.21549Ile Cav3.21951Glu Cav3.22083Leu
Activation V1/2 (mV) −43.81 ± 1.15 (14) −43.75 ± 1.06 (12) −53.47 ± 0.77 (9)⁎⁎⁎ −45.95 ± 1.33 (8) −42.42 ± 1.86 (9)
Activation slope (k, mV) 5.89 ± 0.48 (14) 6.62 ± 0.34 (12) 6.21 ± 0.31 (9) 5.69 ± 0.19 (8) 5.99 ± 0.34 (9)
Inactivation V1/2 (mV) −67.55 ± 1.42 (13) −69.08 ± 1.47 (11) −76.58 ± 0.93 (6)⁎⁎ −67.98 ± 1.03 (6) −73.11 ± 2.65 (6)
Inactivation slope (k, mV) 5.42 ± 0.36 (13) 5.87 ± 0.42 (11) 5.17 ± 0.22 (6) 4.19 ± 0.13 (6) 7.25 ± 0.64 (6)⁎⁎
Activation kinetics @−30 mV (Tau act, ms) 4.47 ± 0.33 (13) 7.99 ± 0.41 (14)⁎⁎ 8.30 ± 0.77 (9)⁎⁎ 3.57 ± 0.22 (8) 6.46 ± 0.86 (9)
Inactivation kinetics @−30 mV (Tau inact, ms) 21.93 ± 2.09 (11) 43.23 ± 3.14 (12)⁎⁎⁎ 83.07 ± 8.47 (7)⁎⁎⁎ 24.52 ± 2.86 (8) 24.60 ± 2.23 (7)
Recovery (Tau, ms) 509.76 ± 30.00 (8) 419.12 ± 14.49 (9)⁎ 1197.60 ± 93.92 (8)⁎⁎⁎ 349.74 ± 15.63 (7)⁎⁎⁎ 389.93 ± 28.89 (6)⁎⁎
Deactivation kinetics @−90 mV (Tau deact, ms) 3.01 ± 0.31 (15) 3.08 ± 0.28 (13) 11.67 ± 1.14 (9)⁎⁎⁎ 2.50 ± 0.16 (12) 3.07 ± 0.35 (9)
Facilitation (fold increase normalized current) 1.12 ± 0.05 (8) 1.34 ± 0.03 (8)⁎⁎⁎ 1.07 ± 0.02 (6) 1.26 ± 0.02 (9)⁎⁎ 1.35 ± 0.05 (9)⁎⁎⁎
Number of recorded cells are indicated in brackets.
⁎ P b 0.05 compared with WT channels.
⁎⁎ P b 0.01 compared with WT channels.
⁎⁎⁎ P b 0.001 compared with WT channels.
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differences in aldosterone levels were observed in cells overexpressing
the mutant forms of Cav3.2 compared to Cav3.2WT after stimulation
with AngII (Fig. 5A to D).
3.6. Effect of Cav3.2Mutations onmRNA Expression of Genes Coding for Key
Proteins of Aldosterone Biosynthesis
In order to gainmechanistic insight into howmutant forms of Cav3.2
increased aldosterone production, we determined the effects of overex-
pressingWT andmutant channels onmRNA expression of genes coding
for key proteins of aldosterone biosynthesis (StAR encoding Steroido-
genic acute regulatory protein, HSD3B1, and HSD3B2 encoding 3β-hy-
droxysteroid dehydrogenase isoform 1 and 2, CYP21A2 encoding
Steroid 21-hydroxylase, and CYP11B2 coding for aldosterone synthase).
In basal conditions, differences in mRNA expression were detected in
cells transfected with Cav3.2196Leu but not with the other mutantFig. 3.Activation, inactivation and deactivation properties ofWT andmutant Cav3.2 channels. A
measured at−30 mV from HPs ranged from−120 to−40 mV (5 s duration, 10 mV increme
inactivation of Cav3.2 WT and mutant Cav3.2 channels. Recovery from inactivation was mea
increasing duration (100 ms to 8 s). D. Deactivation kinetics as a function of the potential for Cchannels (Fig. 6 and Fig. 7). Compared to cells transfected with
Cav3.2WT, cells overexpressing Cav3.2196Leu showed increased StAR (3-
fold; P b 0.01), HSD3B1 (3-fold; P b 0.05), and CYP21A2 (2.3-fold
(P b 0.05) mRNA expression (Fig. 6A, B and D); no differences were ob-
served in HSD3B2 or CYP11B2 expression (Fig. 6C and E).
After K+ stimulation, cells overexpressing Cav3.21549Ile and
Cav3.2196Leu showed increased mRNA expression of StAR (Cav3.21549Ile
1.8 fold, P b 0.05; Cav3.2196Leu 2.8 fold, P b 0.01), HSD3B1 (Cav3.21549Ile
4.6 fold, P b 0.05; Cav3.2196Leu 6 fold, P b 0.01), HSD3B2 (Cav3.21549Ile 3
fold, P b 0.05; Cav3.2196Leu 4.1 fold, P b 0.05), CYP21A2 (Cav3.21549Ile
2.5 fold, P b 0.05; Cav3.2196Leu 2.4 fold, P b 0.05), and CYP11B2
(Cav3.21549Ile 4.7 fold, P b 0.001; Cav3.2196Leu 7.5 fold, P b 0.001) when
compared to cells overexpressing Cav3.2WT (Fig. 6A–E). In cells express-
ing Cav3.21951Glu, K+ stimulation induced an increase in HSD3B1 (1.3
fold, P b 0.05), and CYP11B2 (1.7 fold, P b 0.05) mRNA expression
when compared with cells overexpressing Cav3.2WT (Fig. 7B and E),
while K+ stimulation of cells transfected with Cav3.22083Leu lead to an. Steady-state inactivation curves of Cav3.2WT andmutant Cav3.2 channels. Currentswere
nts). B. Simulated window currents of Cav3.2 WT and mutant channels. C. Recovery from
sured at−30 mV after 1 s depolarization (−30 mV) applied from a HP of−100 mV of
av3.2 WT and mutant channels.
Fig. 4. Voltage dependent facilitation of Cav3.2 channels. A-B. Voltage-dependent
facilitation of Cav3.2 WT (A) and Cav3.22083Leu currents (B). To examine facilitation a
300 ms TP at−50 mV was preceded by a 300 ms conditioning pulse either at−30 mV
or either at +100 mV. The interpulse interval was 1 s. The paired-pulse protocol was
applied at a frequency of 0.066 Hz. C. Facilitation of Cav3.2 WT and mutant channels.
The magnitude of facilitation is determined by the ratio of the current obtained after the
+100 mV conditioning pulse to the current obtained after the −30 mV conditioning
pulse.
Fig. 5. Effect of WT and mutants Cav3.2 on aldosterone production. Basal and stimulated
(AngII or K+) aldosterone production by H295R-S2 cells transfected with WT or mutant
Cav3.21549Ile (A), Cav3.2196Leu (B), Cav3.22083Leu (C), and Cav3.21951Glu (D). 24 h post
transfection, cells were serum deprived (0.1% Ultroser G) for 24 h and then incubated
for another 24 h with fresh serum deprived medium in absence (basal) or presence of
10 nM of AngII (A-II 10 nM) or 12 mM K+ (K+ 12 mM). i) ***P b 0.001 or **P b 0.01 or
*P b 0.05 vs Cav3.2WT basal; ii) ***P b 0.001 or **P b 0.01 vs Cav3.2WT K+, n= 9–12.
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CYP21A2 (2.3 fold, P b 0.05) (Fig. 7A, B, and D).
Treatment with AngII had no effect on StAR, HSD3B1, HSD3B2,
CYP21A2, or CYP11B2 expression in cells overexpressing Cav3.21549Ile
or Cav3.2196Leu compared with cells transfected with Cav3.2WT (Fig.
6A–E) and led to a slight decrease in HSD3B1 (Cav3.22083Leu − 32%,
P b 0.05; Cav3.21951Glu− 35%, P b 0.05) and HSD3B2 (Cav3.22083Leu−
30%, P b 0.05) mRNA expression in cells expressing the mutants
Cav3.22083Leu and Cav3.21951Glu (Fig. 7B and C).
4. Discussion
Mutations in different genes coding for ion channels (KCNJ5 (Choi et
al., 2011) and CACNA1D (Azizan et al., 2013; Scholl et al., 2013)) and
ATPases (ATP1A1 and ATP2B3 (Beuschlein et al., 2013)) have been iden-
tiﬁed in PA. They occur as somatic variants in the case of APA and
germline variants in familial forms and affect regulation of intracellular
ionic homeostasis andmembrane potential, leading to activation of cal-
cium signaling, the major trigger for aldosterone production (Azizan et
al., 2013; Beuschlein et al., 2013; Choi et al., 2011; Fernandes-Rosa et al.,
2014; Scholl et al., 2013). Despite these recent advances, the pathogen-
esis of a large proportion of APA and familial cases of PA has been elu-
sive. The current study suggests that different genetic variants inCACNA1H, coding for the voltage-gated T-type calcium channel Cav3.2,
may be responsible for PA with different phenotypic presentations.
Through WES we have identiﬁed three CACNA1H germline variants in
a patient with early onset PA and multiplex developmental disorder
and in two patients diagnosed with FH-II. Additionally, we also
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tations lead to changes in electrophysiological channel properties, aldo-
sterone production and/or expression of genes coding for steroidogenic
enzymes, supporting a gain of function.
CACNA1H variants have been previously associated with epileptic
disorders (such as childhood absence epilepsy, febrile seizures, myo-
clonic–astatic epilepsy, and juvenile absence epilepsy) (Chen et al.,
2003; Heron et al., 2007; Khosravani et al., 2004; Khosravani et al.,
2005), autism spectrum disorders (Splawski et al., 2006) and chronic
pain in pediatric patients (Souza et al., 2016).More recently, a recurrent
CACNA1Hmutation, p.Met1549Val, has been identiﬁed in a cohort of pa-
tients with PA and hypertension before age 10 with no history of sei-
zures, neurologic or neuromuscular disorders (Scholl et al., 2015).
Family screening revealed autosomal dominant inheritance of the mu-
tationwith incomplete penetrance of the disease, including asymptom-
atic patients.
Our work enlarges the genetic and phenotypic spectrum of PA asso-
ciated with CACNA1Hmutations. In addition to early onset PA and hy-
pertension, patient K055-3 carrying the p.Met1549Ile mutation
presented mild mental retardation, social skills alterations and learning
disabilities and was diagnosed with multiplex developmental disorder
at age 10 years. This phenotype may owe to a gain of function effect of
Cav3.2 in the nervous system, similar to what is observed in patients
carrying germline mutations in another calcium channel gene,
CACNA1D, coding for Cav1.3, who presentwith seizures and severe neu-
rological abnormalities in addition to PA (Scholl et al., 2013). Among pa-
tients carrying the recurrent p.Met1549Val described previously (Scholl
et al., 2015), developmental delay or attention deﬁcit were reported in
twomutation carriers. In our study, CACNA1H variants were also associ-
atedwith familial hyperaldosteronismdiagnosed as FH-II, andwith spo-
radic PA and APA. This phenotypic variability may be explained by
different functional consequences that the different CACNA1H variants
have on channel properties. Differences in clinical presentation where
also observed within family members carrying the recurrent CACNA1H
p.Met1549Val variant, which were attributed to age-dependent vari-
ability or to genetic or environmental modiﬁers (Scholl et al., 2015).
One limitation of the present study is the lack of follow-up data of pa-
tients with familial PA and more detailed clinical information on their
relatives, which prevented deeper phenotype/genotype investigations
in familial PA. Concerning the adrenal phenotype, the presence of addi-
tional somatic genetic variants occuring in the adrenal gland of patients
carrying a germline CACNA1H variant may play a role in the develop-
ment of APA, although no recurrentmutation in anyof the knowndriver
genes has been identiﬁed in tumor DNAof patient K135-1. Also, we can-
not exclude that in some cases bilateral adrenal hyperplasiamight occur
in patients with PA, with a predominant aldosterone-producing nodule
on one side leading to lateralization on AVS and cure after surgery. An
alternative possibility is the involvement of adrenal aldosterone pro-
ducing cell clusters (APCC), which have been shown to carry somatic
mutations in APA driver genes in the normal population. Transition
from APCC to APA, triggered by unknown factors and which has been
evoked as a mechanism for APA development (Nishimoto et al., 2016)
may be favored by germline genetic alterations, includingCACNA1H var-
iants, creating a favorable cellular environment for this transition.Fig. 6. Effect of Cav3.2196Leu and Cav3.21549Ile on mRNA expression of genes involved in
aldosterone biosynthesis. 24 h post transfection, cells were serum deprived (0.1%
Ultroser G) for 24 h and then incubated for another 24 h with fresh serum deprived
medium in absence (basal) or presence of 10 nM of AngII (A-II 10 nM) or 12 mM K+
(K+ 12 mM). Cells were collected for RNA extraction, and real time RT-qPCR was
performed. mRNA levels of StAR, HSD3B1, HSD3B2, CYP21A2 and CYP11B2 were
normalized for CACNA1H expression to correct for transfection efﬁciency. Normalization
for RNA quantity, and reverse transcriptase efﬁciency was performed against three
reference genes (geometric mean of the expression of 18S RNA, HPRT, and GAPDH). Data
are represented as fold increase vs WT in basal condition. i) **P b 0.01 or *P b 0.05 vs
Cav3.2WT basal; ii) ***P b 0.001 or **P b 0.01 or *P b 0.05 vs Cav3.2WT K+, n = 9–12.
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consists of a single polypeptide chain of four homologous domains (I–
IV), each one containing six transmembrane spans (Segments (S) 1–
6), and cytoplasmic N- and C-termini. The pore of T-type channels is
formed by the tetrameric arrangement of the four domains and it is
lined by the S6 segment in the intracellular part, while the S4 segment
serves as the voltage sensor (Perez-Reyes, 2003). The p.Ser196Leu mu-
tation is located in the S4 segment of domain I. Each S4 segment con-
tains positively charged residues on every third position and forms the
voltage sensor, allowing the channel to open and close in response to
changes in membrane potential (Burnay et al., 1994). The substitution
of Leucine for Serine changes a polar uncharged aminoacid into a hydro-
phobic one, which is never found at this position (Burnay et al., 1994). A
similar substitution from a polar uncharged to a hydrophobic residue
has been found in the S4 segment of domain IV of a patient with idio-
pathic generalized epilepsy (p.Thr1733Ala) (Heron et al., 2007), while
substitution from a positively charged to a hydrophobic amino acid in
the S4 segment of domain I and II has been associatedwith autism spec-
trum disorders (Splawski et al., 2006). Themutation p.Met1549Ile is lo-
cated in the S6 segment of domain III. A substitution of the same amino
acid has recently been reported in ﬁve out of 40 subjects with hyperten-
sion and PA before age 10 years (Scholl et al., 2015). The p.Met1549Val
mutation was shown tomodify the functional properties of the calcium
channel, facilitating its opening at more hyperpolarized potentials and
delaying its inactivation, leading to increased aldosterone production
(Reimer et al., 2016). Finally, variants p.Val1951Glu and p.Pro2083Leu
are located at the cytoplasmic C-terminus of the channel. Studies on
Cav3.1, which is closely related to Cav3.2, showed that the C-terminus
determines fast inactivation of this T-type calcium channel (Staes et
al., 2001). Amino acid substitutions in this region of Cav3.2 were
found in patients with epilepsy (p.Arg1892His, p.Arg2005Cys,
p.His2060Arg, p.Arg2077His) (Chen et al., 2003; Heron et al., 2007)
and in autism spectrum disorders (p.Arg1871Gln + Ala1874Val)
(Splawski et al., 2006).
Mutant Cav3.2 channels showed signiﬁcant changes in their electro-
physiological properties. Cav3.21549Ile, similarly to Cav3.21549Val (Scholl
et al., 2015), shows a signiﬁcant shift in activation and inactivation
properties towards more negative potentials. Consequently,
Cav3.21549Ile is activated at less depolarized membrane potentials close
to the resting potential. In addition, this mutant channel exhibits a sig-
niﬁcant slowing of the activation, inactivation and deactivation kinetics
which may greatly contribute to a larger increase in Ca2+ entry. These
data suggest that, similar to Cav3.1, the Met-Phe-Val sequence of the
S6 segment of domain III is implicated in rapid channel inactivation of
Cav3.2 (Marksteiner et al., 2001). The three other mutants also show
electrophysiological modiﬁcations, including slowing of activation and
inactivation kinetics (Cav3.2196Leu), altered steady-state inactivation
(Cav3.2196Leu and Cav3.22083Leu) and increase in voltage-dependent fa-
cilitation (Cav3.2196Leu, Cav3.21951Glu and Cav3.22083Leu). The electro-
physiological properties of these Cav3.2 mutants also suggest a gain of
function phenotype. In idiopathic generalized epilepsy, gain of function
mutations inside the voltage sensor S4 domain IV (p.Thr1733Ala) also
showed a shift of the steady-state inactivation, in addition to a faster re-
covery from inactivation, while those in the cytoplasmic C-termini of
the channel led to slightly faster activation in response to membraneFig. 7. Effect of Cav3.21951Glu and Cav3.22083Leu on mRNA expression of genes involved in
aldosterone biosynthesis. 24 h post transfection, cells were serum deprived (0.1%
Ultroser G) for 24 h and then incubated for another 24 h with fresh serum deprived
medium in absence (basal) or presence of 10 nM of AngII (A-II 10 nM) or 12 mM K+
(K+ 12 mM). Cells were collected for RNA extraction and real time RT-qPCR was
performed. mRNA levels of StAR, HSD3B1, HSD3B2, CYP21A2 and CYP11B2 were
normalized for CACNA1H expression to correct for transfection efﬁciency. Normalization
for RNA quantity, and reverse transcriptase efﬁciency was performed against three
reference genes (geometric mean of the expression of 18S RNA, HPRT, and GAPDH). Data
are represented as fold increase vs WT in basal condition. i) *P b 0.05 vs Cav3.2WT A-II;
ii) **P b 0.01 or *P b 0.05 vs Cav3.2WT K+, n = 9–12.
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from inactivation (p.Arg2005Cys) (Heron et al., 2007).
Altogether, these results show that Cav3.2 mutations identiﬁed in
patients with PA all induce changes in electrophysiological channel
properties supporting a gain of channel activity, which is expected to
generate increased electrical activity. Although qualitatively different,
these modiﬁcations are inferred to increase calcium entry into the cell
and to activate calcium signaling. Results from functional studies in
adrenocortical H295R-S2 cells directly link electrophysiological abnor-
malities to increased aldosteroneproduction. Indeed, transient transfec-
tions of Cav3.21549Ile or Cav3.2196Leu led to signiﬁcant increases in
aldosterone production after stimulation with K+, which was related
to increased expression of genes coding for steroidogenic enzymes, in-
cluding CYP11B2. Although Cav3.21951Glu and Cav3.22083Leu did not
lead to signiﬁcant increases in aldosterone biosynthesis, they also in-
duced increased mRNA expression of a subset of genes coding for key
proteins of aldosterone biosynthesis. We did not observe similar differ-
ences at the basal level (except for Cav3.2196Leu) or after AngII stimula-
tion. This might depend on the particular characteristics of H295R-S2
cells, which show high basal production of aldosterone that may mask
subtle changes induced by Cav3.2 mutations at the basal state in a con-
text of low transfection efﬁciency in these cells. Similarly, the fact that
AngII mainly acts via inositol triphosphate-dependent calcium release
from endoplasmatic reticulum (Burnay et al., 1994) very likely masks
the effect of mutant channels on intracellular calcium levels. Stimula-
tion of cells with K+ appears to be more sensitive for the functional
analysis of mutated voltage-dependent calcium channels, in particular
for T-type calcium channels (Rossier et al., 1996). Indeed, K+-stimulat-
ed aldosterone production from bovine zona glomerulosa cells is corre-
lated with T-type channel activity (Schrier et al., 2001). The fact that
Cav3.2 is the predominant T-type calcium channel in bovine and rat
zona glomerulosa (Schrier et al., 2001), and in our transciptomic analy-
sis in human adrenal cortex and APA, supports the role of Cav3.2 on in-
creased aldosterone production in K+-stimulated H295R-S2 cells.
In conclusion, we have identiﬁed four germline CACNA1Hmutations
in PA patientswith different phenotypic presentations. Thesemutations
induce signiﬁcant changes in channel properties, aldosterone produc-
tion and/or expression of genes coding for steroidogenic enzymes. Iden-
tiﬁcation of new CACNA1H mutations that are associated with early
onset PA and multiplex developmental disorder, familial forms diag-
nosed as FH-II or APA, suggests that CACNA1Hmight be a susceptibility
gene predisposing to PA with different phenotypes, opening new per-
spectives for genetic diagnosis and management of patients with PA.
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